Chronic Hepatitis B Infection: New Approaches towards Cure

Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective at suppressing HBV replication, however, adherence to daily therapy can be challenging. This review discusses recent advances in the development of long-acting formulations for HBV treatment and prevention, which could potentially improve adherence. Promising new compounds that target distinct steps of the virus life cycle are summarized. In addition to treatments that suppress viral replication, curative strategies are focused on the elimination of covalently closed circular DNA and the inactivation of the integrated viral DNA from infected hepatocytes. We highlight promising long-acting antivirals and genome editing strategies for the elimination or deactivation of persistent viral DNA products in development.

[1]  T. Asselah,et al.  Hepatitis D Virus Infection. , 2023, The New England journal of medicine.

[2]  Yang Zhang,et al.  Discovery, optimization and biological evaluation of novel HBsAg production inhibitors. , 2023, European journal of medicinal chemistry.

[3]  Yao-Chun Hsu,et al.  Global burden of hepatitis B virus: current status, missed opportunities and a call for action , 2023, Nature Reviews Gastroenterology & Hepatology.

[4]  S. Oka,et al.  Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men , 2023, Hepatology.

[5]  Wenhai Huang,et al.  The progress of molecules and strategies for the treatment of HBV infection , 2023, Frontiers in Cellular and Infection Microbiology.

[6]  V. Soriano,et al.  Susceptibility to hepatitis B virus infection in adults living in Spain , 2023, Liver international : official journal of the International Association for the Study of the Liver.

[7]  H. Cheng,et al.  Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B , 2023, Medicine.

[8]  A. Lok,et al.  The scientific basis of combination therapy for chronic hepatitis B functional cure , 2023, Nature Reviews Gastroenterology & Hepatology.

[9]  C. la Vecchia,et al.  Cancers attributable to infectious agents in Italy. , 2023, European journal of cancer.

[10]  F. Zoulim,et al.  Eliminating cccDNA to cure Hepatitis B virus (HBV) infection. , 2023, Journal of hepatology.

[11]  H. Gendelman,et al.  An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression , 2022, Science advances.

[12]  J. Young,et al.  Discovery of a first-in-class orally available HBV cccDNA inhibitor. , 2022, Journal of hepatology.

[13]  D. Thomas,et al.  Long-Acting Treatments for Hepatitis B. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Asselah,et al.  Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. , 2022, The New England journal of medicine.

[15]  Chien-Jen Chen,et al.  Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status , 2022, JHEP reports : innovation in hepatology.

[16]  M. Brunetto,et al.  Highly dynamic changes of regional HBV epidemiology over two decades. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  H. Günthard,et al.  HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Paik Lenacapavir: First Approval , 2022, Drugs.

[19]  T. Taddei,et al.  Attacking the public health crisis of hepatocellular carcinoma at its roots , 2022, Hepatology.

[20]  H. Razavi,et al.  The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road , 2022, Journal of Hepatology.

[21]  H. Gendelman,et al.  Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. , 2022, Future microbiology.

[22]  Lalu Muhammad Irham,et al.  Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2022, The lancet. Gastroenterology & hepatology.

[23]  Juan Chen,et al.  SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters , 2022, Frontiers in Microbiology.

[24]  Meghan M. Holdorf,et al.  Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  P. Mangeot,et al.  CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants , 2022, mBio.

[26]  Noele P. Nelson,et al.  Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[27]  S. Delany-Moretlwe,et al.  Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial , 2022, The Lancet.

[28]  C. Steer,et al.  Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing , 2022, Hepatology communications.

[29]  Ciaran M. Lee,et al.  Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes , 2022, The CRISPR journal.

[30]  H. Torres,et al.  Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. , 2022, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  M. Yuen,et al.  RNA interference as a novel treatment strategy for chronic hepatitis B infection , 2022, Clinical and molecular hepatology.

[32]  H. Karimi-Sari,et al.  Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg) , 2022, Journal of clinical medicine.

[33]  P. Venkatesan Long-acting injectable ART for HIV: a (cautious) step forward. , 2022, The Lancet. Microbe.

[34]  G. Papatheodoridis,et al.  Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis , 2022, Journal of gastroenterology and hepatology.

[35]  M. Baum,et al.  CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women , 2022, BMJ Open.

[36]  R. Weiskirchen,et al.  Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases , 2021, Frontiers in Pharmacology.

[37]  Chun‐Xia Zhao,et al.  Lipid Nanoparticles for Drug Delivery , 2021, Advanced NanoBiomed Research.

[38]  H. Hsiao,et al.  Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation , 2021, Journal of personalized medicine.

[39]  H. Gendelman,et al.  Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles , 2021, Nature Communications.

[40]  M. Yuen,et al.  Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study , 2021, JHEP reports : innovation in hepatology.

[41]  Yue Chen,et al.  Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. , 2021, Clinics and research in hepatology and gastroenterology.

[42]  Shaoman Yin,et al.  Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018. , 2021, Hepatology.

[43]  M. Iannacone,et al.  Immunobiology and pathogenesis of hepatitis B virus infection , 2021, Nature Reviews Immunology.

[44]  W. Jiskoot,et al.  mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability , 2021, International Journal of Pharmaceutics.

[45]  Danping Huang,et al.  Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy , 2021, World journal of gastroenterology.

[46]  Anh-Hoa Nguyen,et al.  Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B , 2021, Hepatology.

[47]  Juan Li,et al.  Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Zongguo Yang,et al.  Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis , 2021, Bioengineered.

[49]  Y. Chong,et al.  Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[50]  D. Venzon,et al.  Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. , 2020, Journal of hepatology.

[51]  Yan Huang,et al.  Editorial: tenofovir alafenamide fumarate—a new bullet to prevent mother‐to‐child transmission of hepatitis B virus. Authors' reply , 2020, Alimentary pharmacology & therapeutics.

[52]  J. Sagartz,et al.  CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice , 2020, Molecular therapy. Methods & clinical development.

[53]  M. Motamedi,et al.  Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis , 2020, Frontiers in Pharmacology.

[54]  A. van der Straten,et al.  Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP) , 2020, Pharmaceutics.

[55]  Gene W. Yeo,et al.  Base editing: advances and therapeutic opportunities , 2020, Nature Reviews Drug Discovery.

[56]  V. Soriano,et al.  Advances in hepatitis B therapeutics , 2020, Therapeutic advances in infectious disease.

[57]  J. Borghi,et al.  Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[58]  A. Lok,et al.  Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients , 2020, Clinical and translational gastroenterology.

[59]  J. Niu,et al.  Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  J. McMillan,et al.  Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research , 2020, Expert opinion on drug delivery.

[61]  A. Markham Cabotegravir Plus Rilpivirine: First Approval , 2020, Drugs.

[62]  Y. Lim,et al.  Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[63]  M. Peet,et al.  Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats. , 2020, International journal of pharmaceutics.

[64]  Jonathan T. Su,et al.  Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate , 2020, Pharmaceutical Research.

[65]  H. Gendelman,et al.  A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. , 2020, Nanomedicine : nanotechnology, biology, and medicine.

[66]  Ding‐Shinn Chen,et al.  Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing , 2020, Molecular therapy. Nucleic acids.

[67]  G. Dusheiko Will we need novel combinations to cure HBV infection? , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[68]  Trushar R. Patel,et al.  Host Transcription Factors in Hepatitis B Virus RNA Synthesis , 2020, Viruses.

[69]  Qinghua Zhou,et al.  Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer , 2020, Medicine.

[70]  M. Manoharan,et al.  The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs , 2019, Nature Nanotechnology.

[71]  D. Castor,et al.  The only way is up: priorities for implementing long-acting antiretrovirals for HIV prevention and treatment , 2019, Current opinion in HIV and AIDS.

[72]  M. Buti,et al.  Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference , 2019, Hepatology.

[73]  H. Gendelman,et al.  Synthesis of a long acting nanoformulated emtricitabine ProTide. , 2019, Biomaterials.

[74]  F. Zoulim,et al.  Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial , 2019, Human vaccines & immunotherapeutics.

[75]  M. Maini,et al.  Restoring, releasing or replacing adaptive immunity in chronic hepatitis B , 2019, Nature Reviews Gastroenterology & Hepatology.

[76]  H. Gendelman,et al.  A long acting nanoformulated lamivudine ProTide. , 2019, Biomaterials.

[77]  F. Zoulim,et al.  Therapeutic strategies for hepatitis B virus infection: towards a cure , 2019, Nature Reviews Drug Discovery.

[78]  F. Lu,et al.  [Exosome-mediated CRISPR/Cas9 system targets to cut the intercellular transmission function of hepatitis B virus genome]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[79]  Seth P. Forster,et al.  Exploration of long-acting implant formulations of hepatitis B drug entecavir. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[80]  H. Gendelman,et al.  Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation , 2019, International journal of nanomedicine.

[81]  A. van der Straten,et al.  Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP) , 2019, Pharmaceutics.

[82]  A. Mangia,et al.  Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. , 2019, Gastroenterology.

[83]  Y. Huang,et al.  Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B , 2019, Journal of viral hepatitis.

[84]  J. Sasadeusz,et al.  Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement , 2019, The Medical journal of Australia.

[85]  P. Easterbrook,et al.  Hepatitis B virus infection in children and adolescents. , 2019, The lancet. Gastroenterology & hepatology.

[86]  C. Gersbach,et al.  The next generation of CRISPR–Cas technologies and applications , 2019, Nature Reviews Molecular Cell Biology.

[87]  Zeyu Zhang,et al.  The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis , 2019, BMC cancer.

[88]  W. Talloen,et al.  Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. , 2019, Gastroenterology.

[89]  G. Doncel,et al.  Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV , 2019, Pharmaceutics.

[90]  Md. Sohel Rana,et al.  Interest of Youth Living With HIV in Long-Acting Antiretrovirals , 2019, Journal of acquired immune deficiency syndromes.

[91]  M. Buti,et al.  Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2019, Gastroenterology.

[92]  Maocai Yan,et al.  Entecavir‐loaded poly (lactic‐co‐glycolic acid) microspheres for long‐term therapy of chronic hepatitis‐B: Preparation and in vitro and in vivo evaluation , 2019, International journal of pharmaceutics.

[93]  P. Prathipati,et al.  Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[94]  Q. Bian,et al.  Real‐world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load , 2018, Alimentary pharmacology & therapeutics.

[95]  S. Bao,et al.  Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk , 2018, Expert opinion on biological therapy.

[96]  Y. Choi,et al.  Design and in vivo evaluation of entecavir‐3‐palmitate microcrystals for subcutaneous sustained delivery , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[97]  R. L. Hood,et al.  Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre‐exposure prophylaxis , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[98]  A. Bradley,et al.  Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements , 2018, Nature Biotechnology.

[99]  A. Collier,et al.  Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection. , 2018, Journal of pharmaceutical sciences.

[100]  G. Doncel,et al.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women , 2018, PloS one.

[101]  A. Mangia,et al.  TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. , 2018, Gastroenterology.

[102]  A. Ely,et al.  Gene Therapy for Chronic HBV—Can We Eliminate cccDNA? , 2018, Genes.

[103]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[104]  F. Zoulim,et al.  Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)–Coinfected Patients With High HBV Replication , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  G. V. van Westen,et al.  Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP , 2017, Scientific Reports.

[106]  Anh-Hoa Nguyen,et al.  Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. , 2017, Journal of hepatology.

[107]  Wenzhe Lu,et al.  A novel orally available small molecule that inhibits hepatitis B virus expression. , 2017, Journal of hepatology.

[108]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[109]  G. Lauer,et al.  Hepatitis B virus infection and the immune response: The big questions. , 2017, Best practice & research. Clinical gastroenterology.

[110]  Yu-Hua Li,et al.  Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis , 2017, Clinical and Experimental Medicine.

[111]  A. Collier,et al.  Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma , 2017, AIDS.

[112]  R. Guner,et al.  Adverse effects of oral antiviral therapy in chronic hepatitis B , 2017, World journal of hepatology.

[113]  David R. Liu,et al.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.

[114]  Yan Zhou,et al.  HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. , 2016, Gastroenterology.

[115]  W. Haefeli,et al.  First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. , 2016, Journal of hepatology.

[116]  H. Gendelman,et al.  Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine , 2016, Journal of acquired immune deficiency syndromes.

[117]  J. Jia,et al.  A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B , 2016, International journal of environmental research and public health.

[118]  Shuqin Zhang,et al.  Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.

[119]  K. Jerome,et al.  Genome editing and the next generation of antiviral therapy , 2016, Human Genetics.

[120]  Huiyan Zhang,et al.  Changing etiologies and outcome of liver failure in Southwest China , 2016, Virology Journal.

[121]  F. Zoulim,et al.  New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. , 2016, Journal of hepatology.

[122]  Erica B. Schlesinger,et al.  A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis , 2016, Pharmaceutical Research.

[123]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[124]  T. Therneau,et al.  Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.

[125]  Z. Goodman,et al.  Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B , 2015, Advances in Therapy.

[126]  A. Ely,et al.  Progress and Prospects of Anti-HBV Gene Therapy Development , 2015, International journal of molecular sciences.

[127]  Mark Taylor,et al.  NICE CG178 Psychosis and Schizophrenia in Adults: Treatment and Management – an evidence-based guideline? , 2015, British Journal of Psychiatry.

[128]  Thomas J. Smith,et al.  Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis , 2015, Antimicrobial Agents and Chemotherapy.

[129]  N. Kootstra,et al.  O114 : Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA , 2015 .

[130]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[131]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[132]  Luis Menéndez-Arias,et al.  Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. , 2014, Current opinion in virology.

[133]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[134]  H. Kim,et al.  A guide to genome engineering with programmable nucleases , 2014, Nature Reviews Genetics.

[135]  N. Shelke,et al.  Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy , 2014, PloS one.

[136]  Zhenghong Yuan,et al.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[137]  R. Fontana,et al.  Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B , 2013, Alimentary pharmacology & therapeutics.

[138]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[139]  U. Haberkorn,et al.  Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts , 2013, Hepatology.

[140]  P. Lampertico,et al.  PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history , 2013, Expert review of anti-infective therapy.

[141]  G. Doncel,et al.  A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis , 2012, Antimicrobial Agents and Chemotherapy.

[142]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[143]  Qiang Deng,et al.  Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. , 2011, Journal of hepatology.

[144]  Thuy D. Vo,et al.  Transient cold shock enhances zinc-finger nuclease–mediated gene disruption , 2010, Nature Methods.

[145]  F. Negro Adverse effects of drugs in the treatment of viral hepatitis. , 2010, Best practice & research. Clinical gastroenterology.

[146]  F. Zoulim,et al.  Hepatitis B virus resistance to nucleos(t)ide analogues. , 2009, Gastroenterology.

[147]  R. Perrillo Benefits and risks of interferon therapy for hepatitis B , 2009, Hepatology.

[148]  J. Dienstag Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.

[149]  M. Yuen,et al.  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[150]  F. Chisari,et al.  Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[151]  Leaf Huang LPD Nanoparticles for Gene Delivery , 1999, Nature Biotechnology.

[152]  M. Heikenwalder,et al.  PASylated interferon &agr; efficiently suppresses hepatitis B virus and induces anti‐HBs seroconversion in HBV‐transgenic mice , 2019, Antiviral research.

[153]  C. Sirlin,et al.  Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis , 2017, Abdominal Radiology.

[154]  S. Locarnini,et al.  Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus. , 2016, Cold Spring Harbor perspectives in medicine.

[155]  Jennifer P. Freeling,et al.  Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. , 2015, AIDS research and human retroviruses.